Rybelsus (semaglutide oral) / Novo Nordisk - LARVOL DELTA

Therapeutic Effects of GLP-1 agonist versus SGLT2-i on patients with T2D and MASLD (EASL 2025) - "The aim was to evaluate the comparative effects of oral Semaglutide therapy (GLP-1 agonist) versus Dapagliflozin (SGLT2 inhibitor) in patients with T2D and MASLD. Therefore, the metabolic effects were superior in the group treated with Semaglutide in contrast to the group that received Dapagliflozin. This can be explained by the more important weight loss and improved glycemic control in the first group. Further studies conducted in an ideal time frame are needed to confirm the evidence presented in this research."

Clinical • Hepatology • Inflammation • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

Novo Nordisk has sought approval of oral version of Wegovy - report (SeekingAlpha) - "Novo Nordisk (NVO) earlier this year submitted an application to the U.S. FDA seeking approval of an oral version of its blockbuster GLP-1 weight loss medicine Wegovy (semaglutide). A company spokesperson confirmed the filing to BioPharma Dive. Novo Nordisk reported positive phase 3 data on the new oral semaglutide in May 2023. That study showed a 15% weight loss at a 50 mg dose. The online publication reported that even though the oral semaglutide phase 3 data came out in 2023, it waited to file for approval until recently to focus on other drugs that might have even better results than injectable semaglutide..."

FDA filing • Obesity

Real-world data on the efficacy of oral semaglutide on anthropometric and body composition parameters in patients with obesity (ECO 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Genetic Disorders • Obesity

Oral semaglutide and reduction in major adverse cardiovascular events. (PubMed, J Clin Lipidol) - No abstract available

Adverse events • Journal • Cardiovascular

Carnitine Deficiency Caused by Salcaprozic Acid Sodium Contained in Oral Semaglutide in a Patient with Multiple Acyl-CoA Dehydrogenase Deficiency. (PubMed, Int J Mol Sci) - "Healthcare providers should monitor for carnitine deficiency when administering SNAC-containing medications to at-risk individuals. Furthermore, this case can raise more significant concerns about the potential impact of pharmaceutical excipients like SNAC on metabolic pathways."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Oncology • Type 2 Diabetes Mellitus

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review. (PubMed, Neurol Ther) - " Preclinical studies indicate that select GLP-1 RAs are CNS penetrant; whether GLP-1 RAs reproducibly engage neural targets hypothesized to subserve dimensions of psychopathology (e.g., general cognitive functions) remains incompletely characterized."

Journal • Review • Alzheimer's Disease • CNS Disorders • Diabetes • Genetic Disorders • Metabolic Disorders • Movement Disorders • Obesity • Parkinson's Disease

Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials. (PubMed, Diabetes Obes Metab) - "The magnitude of efficacy for intended therapeutic actions (HbA1c and body weight reduction) varied widely between incretin mimetic glucose-lowering agents. However, larger therapeutic efficacy was not systematically associated with higher GI AE or drug discontinuation rates, indicating better tolerability of the more effective agents/preparations."

Clinical • Journal • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

Oral Semaglutide and Kidney Outcomes in Type 2 Diabetes: A Prespecified Analysis of the SOUL Randomised Cardiovascular Outcomes Trial (ERA 2025) - No abstract available

Clinical • Late-breaking abstract • Cardiovascular • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study. (PubMed, Diabetol Metab Syndr) - "Our study demonstrated that switching to oral semaglutide therapy from DPP-4 inhibitors significantly improved oxidative stress and glycemic parameters, including glucose variability, in patients with T2DM. jRCT1031210620."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

The Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review. (PubMed, J Clin Med) - " Once-daily oral semaglutide is a promising add-on therapy for the treatment of T2DM with or without obesity in reducing cardiovascular risk factors, potentially lowering cardiovascular-related mortality. Thus, once-daily oral semaglutide may offer cardiovascular benefits comparable to the subcutaneous form, with the advantage of improved adherence."

Journal • Review • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Long-Term (24-Month) Follow-up of Indian T2DM Patients on Oral Semaglutide (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Clinical • Metabolic Disorders • Type 2 Diabetes Mellitus

Proof of Concept Validating a Pharmacogenetic Study on the Human Response to Oral Semaglutide (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Biomarker • Metabolic Disorders

Impact of Oral Semaglutide on CV and Kidney Outcomes and Safety Signals (ADA 2025) - No abstract available

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Oral Semaglutide Reduces Cardiovascular Events In People With Type 2 Diabetes With Atherosclerotic Cardiovascular And/or Chronic Kidney Disease: Primary Results From The SOUL Randomized Trial - Darren K. McGuire (ACC 2025) - No abstract available

Clinical • Late-breaking abstract • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Symposium - SOUL Trial—Effects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk (ADA 2025) - No abstract available

Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Time in Tight Range with Oral Semaglutide as an Add on to SGLT2i and Metformin Combination in People with Type 2DM—Real-World Evidence from India (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Clinical • HEOR • Real-world • Real-world evidence • Metabolic Disorders

Comparison of Effectiveness of Canagliflozin 300mg plus Gliptin vs. Oral Semaglutide plus SGLT2i on Cardiorenal Markers in T2DM Patients (ADA 2025) - "Available on Friday, June 20, 2025 at 10:30am CDT."

Clinical • Metabolic Disorders • Type 2 Diabetes Mellitus

Real-World Impact of Oral Semaglutide (SEMA) vs. DPP-4 Inhibitors on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes (T2D)—An Observational Study (PAUSE) (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Clinical • Observational data • Real-world • Real-world evidence • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy and Safety of Oral Semaglutide with or without SGLT2i Background Therapy (ADA 2025) - No abstract available

Clinical • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A single-center, randomized, placebo-controlled, double-blind study: the efficacy and safety of WONDERLAB SHAPE100TM oral probiotics in combination with once-weekly subcutaneous injections of semaglutide in obese people (ChiCTR) - P4 | N=72 | Not yet recruiting | Sponsor: The First Affilliated Hospital, Sun Yat-sen University; The First Affilliated Hospital, Sun Yat-sen University

New P4 trial • Genetic Disorders • Obesity • APOA2 • APOB • LEP

Real-World Data Comparing the Effectiveness of Injectable vs. Oral Semaglutide—Association of British Clinical Diabetologist (ABCD) National Audit (ADA 2025) - "Available on Friday, June 13, 2025 at 08:00am CDT."

Clinical • Real-world • Real-world evidence • Metabolic Disorders

Oral Semaglutide Reduces Cardiovascular Events In People With Type 2 Diabetes With Atherosclerotic Cardiovascular And/or Chronic Kidney Disease: Primary Results From The SOUL Randomized Trial - Darren K. McGuire (ACC 2025) - No abstract available

Clinical • Late-breaking abstract • Atherosclerosis • Cardiovascular • Chronic Kidney Disease • Diabetes • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Online Information About Side Effects and Safety Concerns of Semaglutide: Mixed Methods Study of YouTube Videos. (PubMed, JMIR Infodemiology) - "The analyzed videos lacked coverage of several important aspects, including the lack of long-term data, the persistence of side effects due to the long half-life of semaglutide, and the risk of counterfeit drugs. It is crucial for the public to be aware that videos cannot replace consultations with physicians."

Adverse events • Journal

SPOT-DM: Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus (clinicaltrials.gov) - P2/3 | N=74 | Not yet recruiting | Sponsor: University Health Network, Toronto

New P2/3 trial • Diabetes • Metabolic Disorders • Transplantation

Clinical development of oral semaglutide for the treatment of type 2 diabetes mellitus: focusing on early phase clinical trials. (PubMed, Transl Clin Pharmacol) - "Phase 3 trials, including the Peptide InnOvatioN for Early diabEtes tReatment program, demonstrated significant reductions in HbA1c, weight loss, and cardiovascular safety, positioning oral semaglutide as a transformative option in diabetes care. The study highlights comprehensive clinical strategies and provides an insight into the future development of oral GLP-1 RAs and other oral peptide drugs."

Journal • Review • Cardiovascular • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus